Packard C, Chapman MJ, Sibartie M, Laufs U, Masana L. Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. Heart. 2021;107(17):1369–75. https://doi.org/10.1136/heartjnl-2020-318760.
Article PubMed CAS Google Scholar
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, ESC Scientific Document Group, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88. https://doi.org/10.1093/eurheartj/ehz455.
Cybulska B, Kłosiewicz-Latoszek L, Penson PE, Nabavi SM, Lavie CJ, Banach M, International Lipid Expert Panel (ILEP). How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors. Prog Cardiovasc Dis. 2021;67:65–74. https://doi.org/10.1016/j.pcad.2020.12.008.
Goldstein LB, Toth PP, Dearborn-Tomazos JL, Giugliano RP, Hirsh BJ, Peña JM, et al. American Heart Association Council on Arteriosclerosis,Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Peripheral Vascular Disease; and Stroke Council. Aggressive LDL-C lowering and the brain: impact on risk for dementia and hemorrhagic stroke: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2023;43:e404–42. https://doi.org/10.1161/ATV.0000000000000165.
Article PubMed CAS Google Scholar
Karagiannis AD, Mehta A, Dhindsa DS, Virani SS, Orringer CE, Blumenthal RS, Stone NJ, Sperling LS. How low is safe? The frontier of very low (< 30 mg/dL) LDL cholesterol. Eur Heart J. 2021;42(22):2154–69. https://doi.org/10.1093/eurheartj/ehaa1080.
Article PubMed CAS Google Scholar
Islam SMT, Osa-Andrews B, Jones PM, Muthukumar AR, Hashim I, Cao J. Methods of low-density lipoprotein-cholesterol measurement: analytical and clinical applications. EJIFCC. 2022;33:282–94.
PubMed PubMed Central CAS Google Scholar
Martins J, Steyn N, Rossouw HM, Pillay TS. Best practice for LDL-cholesterol: when and how to calculate. J Clin Pathol. 2023;76:145–52. https://doi.org/10.1136/jcp-2022-208480.
Article PubMed CAS Google Scholar
Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Caudill SP, Dziekonski A, et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem. 2010;56(6):977–86. https://doi.org/10.1373/clinchem.2009.142810.
Article PubMed PubMed Central CAS Google Scholar
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1046-e1081. https://doi.org/10.1161/CIR.0000000000000624
Taageby Nielsen S, Mohr Lytsen R, Strandkjar N, Juul Rasmussen I, Sillesen AS, Vøgg ROB, et al. Significance of lipids, lipoproteins, and apolipoproteins during the first 14–16 months of life. Eur Heart J. 2023;44:4408–18. https://doi.org/10.1093/eurheartj/ehad547.
Article PubMed PubMed Central CAS Google Scholar
Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232(4746):34–47.
Article PubMed CAS Google Scholar
Hochholzer W, Giugliano RP. Lipid lowering goals: back to nature? Ther Adv Cardiovasc Dis. 2010;4(3):185–91.
Article PubMed CAS Google Scholar
Martin SS, Niles JK, Kaufman HW, Awan Z, Elgaddar O, Choi R, et al. Lipid distributions in the Global Diagnostics Network across five continents. Eur Heart J. 2023;44(25):2305–18.
Article PubMed PubMed Central Google Scholar
Langlois MR, Nordestgaard BG, Langsted A, Chapman MJ, Aakre KM, Baum H, et al. European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clin Chem Lab Med. 2020;58(4):496–517.
Article PubMed CAS Google Scholar
Duan Y, Gong K, Xu S, Zhang F, Meng X, Han J. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduct Target Ther. 2022;7:265.
Article PubMed PubMed Central CAS Google Scholar
Sharpe LJ, Coates HW, Brown AJ. Post-translational control of the long and winding road to cholesterol. J Biol Chem. 2020;295:17549–59.
Article PubMed PubMed Central CAS Google Scholar
Perego C, Da Dalt L, Pirillo A, Galli A, Catapano AL, Norata GD. Cholesterol metabolism, pancreatic β-cell function and diabetes. Biochim Biophys Acta Mol Basis Dis 2019;1865(9):2149–56.
Päth G, Perakakis N, Mantzoros CS, Seufert J. PCSK9 inhibition and cholesterol homeostasis in insulin producing β-cells. Lipids Health Dis. 2022;21(1):138.
Article PubMed PubMed Central Google Scholar
Matsui M, Sakurai F, Elbashir S, Foster DJ, Manoharan M, Corey DR. Activation of LDL receptor expression by small RNAs complementary to a noncoding transcript that overlaps the LDLR promoter. Chem Biol. 2010;17(12):1344–55.
Article PubMed PubMed Central CAS Google Scholar
Luo J, Yang H, Song BL. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2020;21(4):225–45.
Article PubMed CAS Google Scholar
Schulz R, Schlüter K-D, Laufs U. Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). Basic Res Cardiol. 2015;110:1–19.
Olsson AG, Angelin B, Assmann G, Binder CJ, Björkhem I, Cedazo-Minguez A, et al. Can LDL cholesterol be too low? Possible risks of extremely low levels. J Intern Med. 2017;281:534–53.
Article PubMed CAS Google Scholar
Goldstein LB, Toth PP, Dearborn-Tomazos JL, Giugliano RP, Hirsh BJ, et al. American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Peripheral Vascular Disease; and Stroke Council. Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2023;43(10):e404–42.
Article PubMed CAS Google Scholar
Bredefeld C, Hussain MM, Averna M, Black DD, Brin MF, Burnett JR, et al. Guidance for the diagnosis and treatment of hypolipidemia disorders. J Clin Lipidol. 2022;16(6):797–812.
Gill PK, Hegele RA. Low cholesterol states: clinical implications and management. Expert Rev Endocrinol Metab. 2023;18(3):241–53.
Article PubMed CAS Google Scholar
Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a southern African population. Atherosclerosis. 2007;193:445–8.
Article PubMed CAS Google Scholar
Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423–7.
Article PubMed PubMed Central CAS Google Scholar
Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631–9.
Article PubMed CAS Google Scholar
Rao AS, Lindholm D, Rivas MA, Knowles JW, Montgomery SB, Ingelsson E. Large-scale phenome-wide Association study of PCSK9 variants demonstrates Protection Against ischemic stroke. Circ Genom Precis Med. 2018;11(7):e002162.
Article PubMed PubMed Central CAS Google Scholar
Ma C, Gurol ME, Huang Z, Lichtenstein AH, Wang X, Wang Y, et al. Low-density lipoprotein cholesterol and risk of intracerebral hemorrhage: a prospective study. Neurology. 2019;93(5):e445–57.
Comments (0)